Q1 loss narrows 81% on tax benefit; 10 Qelbree patent suits filed; SEC probes Sage

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  Net loss narrowed 81% to $2.3M from $11.8M, driven by a $9.7M income tax benefit — operating loss improved only 19% to $8.3M. The tax swing accounts for the entire net-income improvement; operations remain unprofitable.

  MD&A: Income Tax verify on EDGAR →
• high

  Ten new Qelbree patent lawsuits filed against generic challengers (Appco, Somerset, Apotex, Aurobindo, Zydus, others) trigger automatic FDA approval stays through October 2028. Discovery runs through November 2027; trial dates not yet set.

  Legal Proceedings: Qelbree Litigation verify on EDGAR →
• high

  SEC Enforcement Division subpoenaed Sage Therapeutics in October 2024 regarding the zuranolone NDA for major depressive disorder, including FDA communications and material nonpublic information handling. Federal securities class action and three derivative suits also filed against Sage officers/directors.

  Legal Proceedings: Sage Litigation verify on EDGAR →